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Abstract
Background: Sporadic late-onset nemaline myopathy (SLONM) is a rare, late-onset muscle disorder, characterized
by the presence of nemaline rods in muscle fibers. Phenotypic characterization in a large cohort and a
comprehensive overview of SLONM are lacking.
Methods: We studied the clinico-pathological features, treatment and outcome in a large cohort of 76 patients
with SLONM, comprising 10 new patients and 66 cases derived from a literature meta-analysis (PubMed, 1966–
2016), and compared these with 15 reported HIV-associated nemaline myopathy (HIV-NM) cases. In 6 SLONM
patients, we performed a targeted next-generation sequencing (NGS) panel comprising 283 myopathy genes.
Results: SLONM patients had a mean age at onset of 52 years. The predominant phenotype consisted of weakness
and atrophy of proximal upper limbs in 84%, of proximal lower limbs in 80% and both in 67%. Other common
symptoms included axial weakness in 68%, as well as dyspnea in 55% and dysphagia in 47% of the patients. In 53% a
monoclonal gammopathy of unknown significance (MGUS) was detected in serum. The mean percentage of muscle
fibers containing rods was 28% (range 1–63%). In 2 cases ultrastructural analysis was necessary to detect the rods. The
most successful treatment in SLONM patients (all with MGUS) was autologous peripheral blood stem cell therapy. A
targeted NGS gene panel in 6 SLONM patients (without MGUS) did not reveal causative pathogenic variants.
In a comparison of SLONM patients with and without MGUS, the former comprised significantly more males, had more
rapid disease progression, and more vacuolar changes in muscle fibers. Interestingly, the muscle biopsy of 2 SLONM
patients with MGUS revealed intranuclear rods, whereas this feature was not seen in any of the biopsies from patients
without paraproteinemia.
Compared to the overall SLONM cohort, significantly more HIV-NM patients were male, with a lower age at onset
(mean 34 years). In addition, immunosuppression was more frequently applied with more favorable outcome, and
muscle biopsies revealed a significantly higher degree of inflammation and necrosis in this cohort. Similar to SLONM,
MGUS was present in half of the HIV-NM patients.
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Conclusions: SLONM presents a challenging, but important differential diagnosis to other neuromuscular diseases of
adult onset. Investigations for MGUS and HIV should be performed, as they require distinct but often effective
therapeutic approaches. Even though SLONM and HIV-NM show some differences, there exists a large clinico-
pathological overlap between the 2 entities.
Keywords: SLONM, Muscle biopsy, HIV-associated nemaline myopathy, HIV-NM, Monoclonal gammopathy, MGUS, NGS
Background
Sporadic late-onset nemaline myopathy (SLONM) is a
rare, acquired, late-onset muscle disorder with subacute
progression, characterized by proximal muscle weakness
and atrophy, and the presence of nemaline rods in myo-
fibers [1, 2]. Distal muscle weakness [3], dropped head
[4, 5], respiratory failure [6, 7], or dysphagia [8, 9] have
also been reported. SLONM can be associated with a
monoclonal gammopathy of unknown significance
(MGUS) that leads to an unfavorable outcome if un-
treated [10–13].
HIV-associated nemaline myopathy (HIV-NM) is an-
other acquired, late-onset nemaline myopathy, distin-
guished by the presence of nemaline rods in muscle
fibers in the setting of an HIV-infection [14–16]. An
autoimmune mechanism for HIV-NM has been dis-
cussed [17, 18], however, it remains unclear whether
HIV-NM and SLONM represent the same or distinct
disease entities.
Histopathologically, nemaline rods can be identified
on modified Gomori’s trichrome staining (mGT) as sub-
sarcolemmal or intermyofibrillar dark red clusters [19].
Using electron microscopy, the rods appear as electron
dense bodies, sometimes showing continuity with the Z-
discs [20]. Rarely, nemaline bodies can occur inside
myonuclei [4, 12, 21, 22]. Rods also represent the histo-
pathological hallmark of the inherited congenital nema-
line myopathies, which are currently known to be
caused by 11 different genes [23].
Several case reports and small series of patients with
SLONM have been published so far, but a systematic over-
view of SLONM is lacking. Here, we studied the clinico-
pathological features as well as treatment and outcome in
a large cohort of 76 patients with SLONM, comprising 10
new patients and 66 cases derived from a literature meta-
analysis. In addition, we screened 283 myopathy genes
using a targeted next-generation sequencing (NGS) panel
in 6 SLONM patients and compared the phenotypic char-
acteristics of the SLONM cohort (n = 76) with 16 HIV-
NM cases reported in the literature.
Methods
SLONM patient selection
Patients with histologically confirmed SLONM, who ei-
ther presented at the neuromuscular outpatient clinic
(Department of Neurology) or had a muscle biopsy sent
for (re-) evaluation to the Institute of Neuropathology at
the University Hospital RWTH Aachen (Aachen,
Germany), were included in our study. Patients with
nemaline myopathy and a history or symptoms suggest-
ing a congenital myopathy, such as positive family his-
tory for myopathy, the presence of delayed motor
milestones, high-arched palate, scoliosis or muscle hypo-
tonia were excluded. Patients with HIV infection were
also excluded.
Clinical and paraclinical examinations
We performed a detailed neurological examination in-
cluding muscle strength evaluation according to the cri-
teria of the Medical Research Council (MRC) scale.
Blood analyses were obtained including creatine kinase
(CK) (normal in men <190 U/l, women <170 U/l), im-
mune fixation and thyroid function as well as electro-
myography (EMG), nerve conduction studies (NCS),
vital capacity measurement using spirometry, and echo-
cardiography in all patients (Table 1, P1-10). The same
examinations were performed in two patients (Table 1,
P11-P12) who had been previously reported [9, 24], but
who were re-evaluated in the current study and included
for genetic analysis (see below).
Histopathological examination
Open muscle biopsies had been performed for diag-
nostic purposes prior to the study after obtaining the
patients’ written informed consent (Table 1, P1-10).
Biopsies were processed for light microscopy (LM)
and electron microscopy (EM) following standardized
procedures [19]. Electron microscopic studies were
performed in 49 published cases and all of our new
patients but patient 4, in whom only LM was avail-
able. All available LM sections and EM images were
analyzed. Biopsies from two additional patients
(Table 1, P11-P12) who had been previously reported
[9, 24] were re-evaluated in the current study.
Statistical analysis
Statistical analysis was performed using Excel software
(Version 16.0.7030.1021) with the Add-In Real Statistics
Resource Pack (Release 4.3). We tested for normal distri-
butions using the D’Agostino Pearson Omnibus and the
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Table 1 Clinical, paraclinical and muscle biopsy features in SLONM, and comparison with HIV-NM
SLONM HIV-NM
All
SLONM
cases (76)
With
gammopathy
(27/76)
Without
gammopathy
(24/76)
P
1
P
2
P 3 P 4 P 5 P 6 P 7 P 8 P 9 P 10 P 11 P
12
All HIV-NM
cases (15)
History:
Gender 35 m/33f
a
18 m/9f 7 m/17f m f f f f f m f m f f f 13 m/2f a
Age at onset
(mean/range) (y)
52/25–78
a
49/25–78 53/27–78 52 67 61 49 54 32 50 47 51 77 67 54 34/21–49 a
Age at examination
(mean/range) (y)
56/27–79 51/26–75 58/34–79 55 72 67 49 79 34 51 48 52 79 79 60 34/21–49
Duration until diagnosis
(mean/range) (y)
4/0–32 2/0–7 4/0–32 3 5 5 4 25 3 1 3 1 2 2 6 1/0–4
Stable/slow progression 42/50
84%
9/18 50% 17/17 100% + + + + + + + - - + + + 6/10 60%
Rapid progression 8/50 16% 9/18 50% 0/16 0% - - - - - - - + + - - - 3/10 40%
Preceding autoimmune
diseases
8/76 11% 1/27 4% 5/24 21% - - + - - - - - - + - - 0/15 0%
Clinical features (in %):
Weakness:
Neck extensor 31/56 (55) 15/25 (60) 9/20 (45) - - - + - - + + - - + + 3/3 (100)
Neck flexor 22/36 (61) 6/11 (55) 8/13 (62) - - - - + - + + - - + + 1/1 (100)
Abdominal/back 17/25 (68) 8/10 (80) 6/9 (67) - - + - - - + + - + + - 2/2 (100)
Upper limbs 43/52 (83) 19/19 (100) 11/17 (65) + - + + - - + + + - + - 11/11 (100)
Lower limbs 40/49 (82) 17/18 (94) 9/15 (60) + + + - + - - + + - + - 8/8 (100)
Proximal 59/64 (92) 27/27 (100) 18/23 (78) + - + + + - + + + - + - 15/15 (100)
Predominantly
proximal
43/59 (73) 25/27 (93) 14/18 (78) + - + + + - + + + - + - 14/15 (93)
Distal 31/59 (53) 11/22 (50) 10/23 (44) + + - - - - - + - - + - 4/15 (27)
Predominantly
distal
4/31 (13) 0/11 (0) 2/10 (20) - + - - - - - - - - - - 0/4 (0)
Facial weakness 17/48 (35) 7/19 (37) 2/17 (12) - - - - - - - - - - - + 0/4 (0)
Ophthalmoparesis 1/21 (5) 0/7 (0) 1/8 (13) - - - - - - - - - - - + 0/4 (0)
Ptosis 2/16 (13) 1/6 (17) 1/8 (13) - - - - - - - - - - - + 0/4 (0)
Dysphagia 21/45 (47) 12/22 (55) 5/16 (31) + - - + - + - - - - - + 1/5 (20)
Dysarthria 6/17 (35) 4/8 (50) 1/7 (14) + - - - - - - - - - - + 0/0 (0)
Dyspnea 17/31 (55) 9/13 (69) 3/7 (43) + - + + - + - - - - - - 0/1 (0)
Muscle atrophy 47/53 (89) 23/24 (96) 15/18 (83) + - - + - - + - + + + + 6/6 (100)
Myalgia 20/47 (43)
a
5/17 (29) 5/17 (29) - - + + + + + - - - + - 4/4 (100) a
Cramps 5/14 (36) 1/4 (25) 1/7 (14) - - - - - - - - - - + - 0/0 (0)
Fasciculations 2/13 (15) 1/6 (17) 0/7 (0) - - - - - - - - - - - - 0/0 (0)
Deep tendon reflexes:
normal 15/38 (11) 6/12 (50) 5/13 (39) - - - + + + - + - + - - 5/8 (63)
increased 4/38 (39) 1/12 (8) 2/13 (15) - - - - - - - - + - - + 0/8 (0)
decreased or absent 19/38 (50) 5/12 (42) 6/13 (46) + + + - - - + - - - + - 3/8 (38)
Paraclinical examination (in %):
IgG gammopathy
present
27/51 (53) 27/27 (100) 0/24 (0) + - - + NA - - + + - - - 3/6 (50)
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Table 1 Clinical, paraclinical and muscle biopsy features in SLONM, and comparison with HIV-NM (Continued)
kappa 14/27 (52) 14/27 (52) 0/24 (0) + - - - NA - - - + - - - 1/3 (33)
lambda 11/27 (41) 11/27 (41) 0/24 (0) - - - + NA - - + - - - - 2/3 (67)
kappa + lambda 1/27 (4) 1/27 (4) 0/24 (0) - - - - NA - - - - - - - 0/3 (0)
multiple myeloma 1/27 (4) 1/27 (4) 0/20 (0) - - - - NA - - - - - - - 0/0 (0)
CK with mean/range
[number of
patients examined]
2.6/1–
55 N [60/
76]
1.5 N/1–4 N
[24/27]
1.9 N/1–17 N
[23/24]
N N 2 N 3 N NA 2 N 17 N 2 N N N 2 N N 1.8 N/1–
5 N [13/15]
Respiratory insufficiency 11/20 (55) 6/9 (67) 3/8 (38) + NA - + - + - - - - - - 0/0 (0)
Cardiomyopathy 3/19 (16) 1/5 (20) 2/7 (29) - NA - dil. - dil. - - - - - - 0/0 (0)
Electromyogram
normal 2/63 (3) 0/27 (0) 2/21 (10) - - - - - - - - - + - - 0/12 (0)
myopathic 53/63 (84) 24/27 (89) 16/21 (76) - + - + + + + + + - + + 12/12 (100)
mixed 6/63 (10) 3/27 (11) 2/21 (10) + - - - - - - - - - - - 0/12 (0)
neurogenic 2/63 (3) 0/27 (0) 1/21 (5) - - + - - - - - - - - - 0/12 (0)
Genetic panel analysis
performed
- + - - - + + - - + + +
Muscle biopsy: VL TA VL D GM D QF VL QF VL BF SC
% of rod containing
cells with mean/range
[number of patients
with available data]
28/1–63
[36/76]
30/3–63 [12/
27]
22/1–50 [14/
24]
3 44 3 43 NA 24 NA 16 28 5 14 35 45/35–50
[3/15]
Intranuclear rods 4/24 (17) 2/9 (22) 0/9 (0) - - - - NA - - - - - - - 0/0 (0)
Muscle fiber atrophy 45/45
(100)
15/15 (100) 13/13 (100) + + + + + + + + + + + + 14/14 (100)
Internalized nuclei 27/37 (73) 10/13 (77) 5/11 (46) + + + + + - - + - - - - 7/7 (100)
Myofibrillar
disintegration
21/24 (88) 8/8 (100) 6/9 (67) + + - + NA + + + + - + - 2/2 (100)
Lobulated/trabeculated
fibers
17/33 (52) 7/14 (50) 9/19 (50) - + - + + - - - - - - + 1/1 (100)
Endomysial fibrosis 17/26 (65) 6/8 (75) 4/9 (44) + + - + NA + - + - - - + 1/1 (100)
Inflammatory infiltrates 9/53 (17) 3/17 (18) 2/22 (9) - - - - - - - - - - - - 6/14 (43)
Necrotic fibers 7/28 (25)
a
3/10 (30) 2/12 (17) + - - - NA + + - - - - - 4/5 (80) a
Core-like areas 11/16 (69) 5/6 (83) 3/7 (43) + + + - NA - + + + - - - 0/0 (0)
Vacuolar changes 11/20 (55) 5/7 (71) 1/8 (13) + - - + + - + - - - +/− - 5/5 (100)
Mitochondrial changes 11/18 (61) 2/5 (40) 3/7 (17) - - unsp. - + - - + - unsp. unsp. - 1/2 (50)
Therapy (and favorable outcome):
Immunosuppressive
agents
36/58 (12/
36) a
19/24 (6/19) 9/17 (2/9) +
(+)
- - +
(−)
- - +
(+)
+
(+)
+
(NA)
- - - 8/10 (8/8) a
Intravenous
Immunoglobulins
11/58 (5/
11)
7/24 (3/7) 4/17 (2/4) - - - - - - +
(+)
- - - - - 2/10 (2/2)
Stem cell therapy 7/58 (6/7) 7/24 (6/7) 0/17 (0/0) - - - - - - - +
(+)
+
(NA)
- - - 0/10
Plasmapheresis 3/58 (1/3) 2/24 (0/2) 0/17 (0/0) - - - +
(−)
- - - - - - - - 1/10 (1/1)
Noninvasive ventilation 3/58 0/24 2/17 + - - - - + - - - - - - 0/10
In bold, statistically significant differences between SLONM with and without monoclonal gammopathy are indicated
HIV-NM HIV-associated nemaline myopathy, m male, f female, y years, + symptom/feature present, NA not available, − symptom/feature not present, IgG immuno-
globulin G, CK serum creatine kinase, N normal value (men <190 U/l, women <170 U/l), dil. dilated cardiomyopathy, VL musculus vastus lateralis, TA musculus tibi-
alis anterior, D musculus deltoideus, GM musculus gluteus medius, QF musculus quadriceps femoris, BF musculus biceps femoris, SC musculus
sternocleidomastoideus, unsp. unspecific mitochondrial changes
a indicates statistically significant differences between all SLONM cases and HIV-NM
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Shapiro-Wilk normality tests and compared normally
distributed independent samples using Welch’s t-test,
and non-normally distributed independent samples
using the Mann-Whitney U test. For categorical vari-
ables, the two-tailed Fisher’s exact test was applied. P-
values less than 0.05 were considered to be statistically
significant.
Targeted next-generation sequencing (NGS) gene panel
In 6 SLONM patients without MGUS, targeted NGS
was performed using a focused panel of 283 genes
(CeGat, Tübingen, Germany). After obtaining written in-
formed consent from each patient, peripheral blood
samples were taken and DNA was extracted following
standard procedures. The gene panel contained 73 genes
that have so far been associated with congenital or distal
myopathies, including genes known to cause congenital
nemaline myopathy. Of these 73 genes, all variants were
further considered. In addition, 210 genes related to di-
verse myopathies were included, in which only variants
that were either marked as “known pathogenic” in the
Human Genome Mutation Database (HGMD®), pro-
duced a STOP codon, resulted in a frameshift or were
located in an essential splice site, were taken into further
consideration. The applied prediction programs were
Mutation Taster (MT), PolyPhen-2 (PP-2), PROVEAN,
SIFT, Splice-Prediction Program NG2: NetGene2 Server,
and Splice-Site Prediction by Neural Network.
Meta-analysis of the literature
We performed a systematic literature search in PubMed
for SLONM cases from 1966 to 2016. All articles written
in English, German and French were considered. The
same inclusion and exclusion criteria that were used in
our study were applied, which resulted in 46 publica-
tions comprising 66 SLONM patients in total (Table 1).
In order to compare the features of SLONM patients
with HIV-associated nemaline myopathy (HIV-NM), we
performed an additional literature search for patients
with HIV-NM. This resulted in 10 publications compris-
ing 16 cases of HIV-NM (Table 1).
Results
Clinical and paraclinical features of patients with SLONM
(Table 1)
Our SLONM study cohort comprised 10 new patients
and 66 cases culled from the literature (Table 1). Mean
age at symptom onset was 52 years, ranging from 25 to
78 years. In half of the patients, first symptoms occurred
between 45 and 60 years of age. Sixty percent were diag-
nosed within the first 2 years after symptom onset, while
the longest diagnostic delay was 32 years (Table 1).
At disease onset, 80% of the patients presented with
muscle weakness of the proximal lower and/or upper
limbs. Neck extensor weakness (dropped head) or dys-
pnea were the only presenting symptoms in four cases
each (8%). In two patients, isolated dysphagia marked
the beginning of the disease (4%). During the disease
course, the predominant clinical phenotype consisted of
weakness and atrophy affecting the proximal upper
limbs in 84%, proximal lower limbs in 80%, and both
proximal upper and lower limbs in 67% as well as axial
weakness (68%). Dyspnea developed in 55%, dysphagia
in 47% of the patients. Muscle weakness progressed
slowly in most SLONM patients. In one third, there was
evidence of facial weakness (35%) or dysarthria (35%).
Myalgia occurred in 43%, cramps in 36%, and fascicula-
tions in 15%. Other symptoms presented more infre-
quently: predominantly distal weakness was seen in four
patients (13%), ptosis in two patients (13%), and
ophthalmoparesis was noted in one patient (5%)
(Table 1).
In 53% of patients with SLONM, an MGUS (IgG) was
detected in serum (Table 1). Urine investigations (per-
formed in 5 patients) did not reveal the presence of
monoclonal immunoglobulins, except for one case (how-
ever, without underlying hematological malignancy) [25].
Fifty-two percent of the MGUS patients had kappa light
chains, 41% lambda, and one patient presented with
both kappa and lambda light chains in the serum [26].
An underlying multiple myeloma was found in only one
case [27]. Serum CK was mostly normal (72%) or only
slightly increased (<3 N; 22%). Three cases presented
with hypothyroidism, which could be explained by amio-
darone intake in one patient (P4). In the other two, anti-
thyroid peroxidase antibodies and anti-thyroglobulin
antibodies were negative in serum. TSH was increased
in one [28] and decreased in another [29] patient. Elec-
tromyography (EMG) mainly showed myopathic changes
(84%). Ten percent of patients showed a mixed pattern
on EMG, two patients presented a purely neurogenic
(3%) ((P3) and [30]) and two more a normal pattern
(3%) ((P9) and [31]). Respiratory insufficiency was de-
tected by spirometry in 55%. Dilated cardiomyopathy
was present in 11% of patients.
Muscle biopsy findings in patients with SLONM (Table 1)
Nemaline bodies were visible by LM in all except 2 biop-
sies (P2, P7), in which EM was necessary to detect the
rods, which were situated in the sarcoplasm and/or
underneath the sarcolemma. Interestingly, intranuclear
rods were present in 17% of the cases, but always com-
bined with intrasarcoplasmic rods. The mean percentage
of muscle fibers containing rods was 28%, varying from
1 to 63% (Table 1). Muscle fiber atrophy was present in
all biopsies. Further frequent histopathological findings
included myofibrillar disintegration (88%), core-like
areas (69%), lobulated fibers (52%) and vacuolar changes
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(55%). Fiber necrosis was present in 25% and inflamma-
tory infiltrates were found in 17% of the biopsies. The
infiltrates were restricted to perivascular areas in 2 cases,
whereas additional more widespread endomysial infil-
trates were observed in the others. Mitochondrial
changes (ragged-red fibers, COX-negative fibers and/or
paracrystalline inclusions on EM) occurred frequently
(64%). However, these could be explained at least in part
as an unspecific age-related phenomenon.
Treatment in patients with SLONM (Tables 1 and 2)
The most common treatment in SLONM patients was
immunosuppressive therapy (62%), mainly consisting of
steroids, with improvement of muscle strength in one
third of the patients (Tables 1 and 2). Intravenous im-
munoglobulins (IVIg) were administered in 19%; in one
third of these cases improvement in muscle strength was
achieved. Plasmapheresis was performed in 3 patients,
which led to a partial improvement in one of them. The
most successful treatment in SLONM patients was high-
dose melphalan followed by autologous peripheral blood
stem cell transplantation (auto-PBSCT), resulting in an
improvement in 6/7 treated patients (86%). This treat-
ment was performed only in SLONM patients with
MGUS. Noninvasive ventilation (NIV) was successful in
4 patients with respiratory insufficiency. Invasive ventila-
tion was performed in one case [6]. All therapeutic regi-
mens and outcomes in all patients for whom this
information was available (n = 58) are listed in Table 2.
Comparison between SLONM patients with and without
MGUS (Table 1)
SLONM and MGUS affected significantly more males
(p = 0.012). Age at onset did not differ significantly be-
tween the two groups (p = 0.34). SLONM patients with
MGUS showed a significantly more rapid disease pro-
gression (p = 0.0010). Bulbar weakness resulting in dys-
phagia, dysarthria, and dyspnea was moderately, but not
significantly more frequent in patients with MGUS (p =
0.20–0.36; Table 1). Muscle weakness in upper (p =
0.0064) and lower (p = 0.030) limbs was significantly
more common in patients with MGUS. Although facial
(p = 0.13), neck extensor (p = 0.38), trunk weakness (p =
0.63), and respiratory insufficiency (p = 0.35) were more
commonly present in patients with MGUS, the differ-
ences were not statistically significant. Treatment re-
sponse to immunosuppressive drugs (p = 0.69) or IVIg
(p = 1.00) did not differ significantly between patients
with and without MGUS. Plasmapheresis or melphalan
followed by auto-PBSCT was only applied in patients
with MGUS.
Muscle biopsy of 2 SLONM patients with MGUS re-
vealed intranuclear rods, whereas this feature was not
observed in patients without paraproteinemia. Vacuolar
changes in muscle fibers were significantly more fre-
quent in SLONM with gammopathy than without (p =
0.041). Myofibrillar disintegration (p = 0.21), inflamma-
tory infiltrates (p = 0.64), fiber necrosis (p = 0.62), and
core-like areas (p = 0.27) were noted more frequently in
SLONM patients with MGUS. However, these differ-
ences did not reach significance (Table 1).
Comparison between patients with SLONM and HIV-NM
(Table 1)
There were significantly more males affected by HIV-
NM compared to the SLONM cohort (p = 0.01). Age at
onset of HIV-NM cases was significantly lower in com-
parison to SLONM patients (p = 0.01). No significant
differences were noted in disease progression (p = 0.37)
or in any of the clinical features (p > 0.05) except for the
occurrence of myalgia in patients with HIV-NM (p =
0.043). Facial or respiratory weakness has not yet been
reported in patients with HIV-NM. Immunosuppressive
therapy (steroids) was administered more frequently in
HIV-NM (p = 0.09), with a significantly more favorable
outcome (p = 0.00071). The two muscle biopsy features
that significantly distinguished HIV-NM from SLONM
were the appearance of inflammatory infiltrates (p =
0.034) and fiber necrosis (p = 0.014). Interestingly,
MGUS was detected in half of the HIV-NM patients,
similar to the SLONM cohort.
According to the Classification of the United States
Center for Disease Control and Prevention [32], the
HIV-status in patients with HIV-NM was heterogeneous
(infection stage 1 in five patients; stage 2 in two patients;
stage 3 in one patient). The infection stage of the other
eight patients remained unknown due to the absence of
information in the literature regarding CD4-positive cell
count and stage 3-defining opportunistic diseases.
Genetic analyses using a targeted NGS gene panel
(Additional file 1: Table S1)
The variants identified by targeted NGS, after applying a
panel of 283 genes, in 6 SLONM patients without
MGUS (Table 1) are summarized in Additional file 1:
Table S1. We did not identify variants in any of the 11
known genes causing congenital nemaline myopathy
(TPM3, NEB, ACTA1, TPM2, TNNT1, KBTBD13, CFN2,
KLHL40, KLHL41, LMOD3, MYPN). In two patients (P2,
P11), a distinct variant of unknown significance was
identified in the ryanodine receptor 1 gene (RYR1). Both
RYR1 variants have not been reported before.
There were no common variants among the six
SLONM patients in any of the genes tested. The variants
identified were heterozygous and for the most part, of
unknown significance (Additional file 1: Table S1). In P2
a known mutation was identified in SCN11A that has
previously been associated with small-fiber neuropathy
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Table 2 Treatment and outcome in patients with SLONM
(novel patients P1-10 and literature data)
Ref. Treatment Outcome
P 1 a steroids + NIV R: improvement of limb and
respiratory strength
P 2 NA NA
P 3 analgetics + physiotherapy NA
P 4 a steroids + plasmapheresis NR, cardiac decompensation
cyclophosphamide +
rituximab
R: stabilisation of weakness
P 5 none NA
P 6 NIV NA
P 7 IVIg + steroids R: increased muscle strength, CK
remained increased
P 8 a auto-PBSCT +melphalan +
dexamethasone +
lenalidomide
R: increased muscle strength
P 9 a auto-PBSCT + steroids NA
P 10 none NA
[24]
(P
11)
none NA
[9]
(P
12)
none NA
[54]
a
auto-PBSCT +melphalan R: paraprotein in serum + rods
disappeared, increased muscle
strength
[12]
a
steroids NR: died within 1y
[12]
a
steroids NR: died within 1y
[12] steroids NR
[12] steroids NR: stable
[12]
a
steroids NR: died within 1y
[12] steroids NR: stable 14y after onset
[12] steroids + IVIg +
methothrexate
NR: stable 6y after onset
[12]
a
steroids +
cyclophosphamide + IVIg
NR: stable 4,5y after onset
[12] none NA
[12] none NA
[12] none NA
[12] none NA
[12] none NA
[12] none NA
[11]
a
plasmapheresis NR
steroids + azathioprine R: increased muscle strength,
myalgia disappeared, serum
paraprotein level decreased;
weakness relapsed after
discontinuation; stable under long-
term medication
Table 2 Treatment and outcome in patients with SLONM
(novel patients P1-10 and literature data) (Continued)
[49] steroids + azathioprine +
mycophenolate mofetil
NR: stable for 2y
rituximab +
cyclophosphamide
R: increased muscle strength,
followed by stabilization
[51]
a
auto-PBSCT +melphalan R for 4 m, followed by further loss
of muscle strength
bortezomib +
dexamethasone
R: muscle strength improved
auto-PBSCT +melphalan R: for 1y, followed by further loss of
muscle strength
bortezomib +
cyclophosphamide +
dexamethasone
R: clinical improvement,
paraprotein in blood disappeared
[10]
a
plasmapheresis PR: increased bulbar and neck
strength, other muscles NR
steroids +
cyclophosphamide
PR: increased muscle strength +
vital capacity, paraprotein level in
blood decreased, patient still
disabled
[38] steroids + azathioprine NR
[8] steroids NR
[52]
a
riluzole NR
IVIg NR
[26]
a
steroids + mycophenolate
mofetil
PR: increased muscle strength in
legs, neck extensor weakness
progressed
IVIg, steroids +
mycophenolate mofetil
R: slow modest increase of muscle
strength for 6 months
[57] posterior cervical orthodesis R: improved head drop, minimal
rotatory restriction
[13]
a
steroids +
cyclophosphamide + IVIg +
rituximab
NR: died 21 m after onset
[6] NIV condition stabilized, orthopnea
disappeared, weakness remained
stable
[31] peridural infiltration R: improvement of lumbar
cruralgia, stable for 3y
[5] steroids NR
[58]
a
IVIg + steroids NR
auto-PBSCT +melphalan R: increased muscle strength over
1y, further decrease in muscle
strength after 2y
[25]
a
IVIg R: increased muscle strength over
2y with almost complete
resolution, stable after 3y therapy
[25]
a
IVIg + steroids +
mycophenolate mofetil
R: increased muscle strength after
1y, but significant weakness
remained
[27]
a
lenalidomide +
dexamethasone
R: significantly increased muscle
strength over 3 m, continuing for
4y
[48]
a
auto-PBSCT +melphalan R: increased muscle strength over
1y, monoclonal protein level in
blood undetectable
Schnitzler et al. Orphanet Journal of Rare Diseases  (2017) 12:86 Page 7 of 12
[33]. Our patient did not, however, show any symptoms
or signs compatible with small-fiber neuropathy. In P10
a heterozygous variant in SH3TC2 was identified; how-
ever, no additional mutation could be found. Homozy-
gous mutations in the SH3TC2 gene cause autosomal
recessive Charcot-Marie-Tooth neuropathy [34], hetero-
zygous mutations can cause subtle autosomal dominant
distal neuropathy [35]. In the current example, the pa-
tient did not show any signs of neuropathy.
Discussion
The clinical presentation of progressive weakness and at-
rophy of proximal upper or lower extremity and axial
muscles, accompanied by dyspnea and/or dysphagia,
represented the predominant clinical phenotype of
SLONM. MGUS was a major feature, present in half of
the patients, which was not only associated with more
rapid disease progression, but also with a favorable re-
sponse to treatment, especially with melphalan/auto-
PBSCT.
Neck extensor weakness, sometimes resulting in
dropped head, occurred in more than half of the
SLONM patients during their disease course. In six
cases, dropped head was an initial symptom; accompan-
ied by limb weakness in four, by dysphagia in one pa-
tient, and as an isolated finding in another case.
Respiratory affection resulting in dyspnea was present in
four patients at disease onset. Interestingly, 3 of these 4
patients with dyspnea as a presenting symptom did not
suffer symptoms from insufficient breathing prior to
presentation. This lack of respiratory symptoms is con-
sidered to be due to the slowness of respiratory decline
in SLONM.
Most patients presented with myopathic or mixed
EMG patterns. However, one published case [30] and
one of our patients (P 3) showed a neurogenic EMG pat-
tern. Neurogenic EMG patterns can appear in severe
chronic myopathies (in so-called ‘end-stage’ muscle) [36,
37]. This could explain at least one of the two cases with
a neurogenic EMG [30], as this patient died as the result
of her disease one year after presentation. In contrast,
the other patient (P 3) did not present a particularly se-
vere chronic myopathy. However, this patient suffered
from chronic lower back pains radiating in the legs,
which may explain the neurogenic changes on EMG in
this patient. An additional peripheral neuropathy was
excluded by nerve conduction studies in both patients.
In fact, SLONM should be considered in the differential
diagnosis of sporadic inclusion body myositis (sIBM), idio-
pathic inflammatory myopathies (IIM) and amyotrophic
lateral sclerosis (ALS). ALS, similar to SLONM, can present
similarly with dropped head, bulbar weakness, dyspnea and
fasciculations. There is even more overlap between IIM
and SLONM; however, the former usually presents with
high serum CK levels, while the latter shows only slight ele-
vations. Inflammatory infiltrates are usually a prominent
histopathological feature of IIM, but can also appear in
SLONM. However, among the IIMs, polymyositis and spor-
adic inclusion body myositis (sIBM) are characterized by
direct infiltration of muscle fibers by cytotoxic T-
lymphocytes immunoreactive for CD8, which was absent in
our SLONM cases. Perifascicular muscle fiber atrophy and
loss of endomysial capillaries, typically found in dermato-
myositis, were also absent in our cases. Sporadic inclusion
body myositis may share many clinical similarities with
SLONM, including age at onset in late adulthood, weakness
of the proximal lower limbs and dysphagia. However, pre-
dominantly distal involvement is uncommon in SLONM,
in contrast to sIBM. Histopathologically, both sIBM and
SLONM present a myopathic pattern, but we could not
identify any inclusion bodies (tubulofilamentous inclu-
sions), and only rarely rimmed vacuoles in the SLONM co-
hort [38, 39]. Furthermore, in patients with sIBM, nemaline
rods do not appear within muscle fibers.
Rarely, SLONM has been reported in combination
with thyroid dysfunction. In our study, TSH has been in-
creased in one and decreased in another patient. Since
both hyper- and hypothyroidism, as such, may cause my-
opathy [40], a direct impact of the change in thyroid
hormones on muscle might contribute to the disease.
Table 2 Treatment and outcome in patients with SLONM
(novel patients P1-10 and literature data) (Continued)
[3] steroids NR
[21] steroids + azathioprine NR
[50] IVIg + steroids R: increased muscle strength
[55]
a
steroids NR
auto-PBSCT +melphalan R: increased muscle strength over
15 m
[1] steroids NR
[1] a steroids NR
[4] steroids NR
[59]
a
steroids + azathioprine PR: myalgia disappeared, but
weakness progressed
[60] steroids R: increased muscle strength,
relapse after discontinuation of
therapy
[61] steroids + azathioprine NR
[29] steroids + IVIg NR: skin rash disappeared,
weakness progressed
[62]
a
steroids + IVIg NR
[63] NIV R: respiratory weakness resolved
NIV noninvasive ventilation, NA not available, R responsive, PR partially
responsive, NR not responsive, IVIg intravenous immunoglobulins, CK creatine
kinase, auto-PBSCT autologous peripheral blood stem cell therapy, y years,
m months
a Patients with monoclonal gammopathy
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Several clinical clues, including age at onset, distin-
guish SLONM from congenital nemaline myopathies.
Mean age at onset in the SLONM cohort was
52 years, whereas patients with hereditary nemaline
myopathy usually develop symptoms during infancy
or early childhood. Furthermore, perinatal hypotonia,
delayed motor milestones, scoliosis and a high-arched
palate are features of congenital nemaline myopathies
and were therefore exclusion criteria for our study.
Histopathologically, fiber type 1 predominance, which
is typically seen in the congenital forms, was not
present in the SLONM cohort. Both congenital and
late-onset nemaline myopathies are characterized by
the presence of rods in the muscle fibers [1, 41]. Our
genetic analysis did not disclose any mutations in
genes known to cause congenital nemaline myopathy.
We did not include the very recently reported myo-
palladin gene (MYPN) in our gene panel, which in
case of mutations was shown to cause nemaline my-
opathy as well [42]. Thus, mutations in MYPN were
not searched for in our SLONM cohort. Furthermore,
we did not perform an analysis of copy number varia-
tions. In intranuclear rod myopathy, which is a con-
genital nemaline myopathy with more severe disease
course, nemaline rods are frequently found inside
myonuclei [43]. Until recently, the only known causa-
tive gene was ACTA1 [44]. However, very recently,
mutations in the myopalladin gene (MYPN) were also
found to cause intranuclear rods [44], in a relatively
mild, childhood- to adult-onset nemaline myopathy
with slowly progressive muscle weakness. The publi-
cation did not include any patients with SLONM that
met our inclusion criteria, as three patients experi-
enced first symptoms in their first decade and the
fourth patient showed a positive family history for
myopathy with consanguinity and neonatal muscular
weakness. Interestingly, the muscle biopsy of two
SLONM patients with MGUS and of two SLONM pa-
tients lacking immunoelectropheresis revealed intra-
nuclear rods, whereas this feature was not seen in
any of our SLONM patients without paraproteinemia.
In all four cases with SLONM and intranuclear rods,
nemaline bodies were also present in the sarcoplasm
[4, 12, 21]. Genetic analysis of ACTA1 was not per-
formed in any of the four cases. The clinical pheno-
type of patients with SLONM with intranuclear rods
was not significantly different compared to other pa-
tients with SLONM. In SLONM, nemaline rods are
the most striking feature, but other unspecific
changes such as fiber atrophy, internalization of nu-
clei, myofibrillar disintegration were also frequent.
Mitochondrial changes, including ragged-red fibers,
COX-negative fibers and/or paracrystalline intramito-
chondrial inclusions detectable by EM, occurred
frequently (64%). These findings might be considered
unspecific and age-related in part; however, a more
direct effect of Z-disc remodeling on skeletal muscle
fiber mitochondria cannot be excluded.
HIV-associated nemaline myopathy showed the same
constellation of features seen in SLONM, including
proximal limb weakness, myopathic EMG and slightly
elevated serum CK levels. However, HIV-NM appears to
be more confined to certain muscle groups, since neither
facial nor respiratory involvement has been reported to
date. Apart from one patient with dysphagia, bulbar
weakness has not been described either. Interestingly,
the majority of patients (73%) showed clinical signs of
myopathy before the HIV infection was detected. There-
fore, it is important to screen (especially younger) pa-
tients with SLONM for HIV infection. Of note, one case
has even been described with negative serology at pres-
entation with HIV seropositivity developing only a year
after myopathy onset [45]. Histopathologically, there
were marginal differences: rods were smaller with <1 μm
radius [15, 46] and they did not appear inside the nu-
cleus in HIV-NM. Moreover, we observed significantly
more frequent myonecrosis and inflammatory infiltrates
in HIV-NM. The most compelling difference, however,
is the good clinical response of treated HIV-NM cases to
immunosuppressive therapy. Combined with muscle in-
volvement during the early stage of HIV infection, this
finding might suggest either a direct impact of the viral
particles on the formation of rods or an immunological
trigger, rather than a degenerative mechanism due to T-
cell suppression/immunodeficiency. An HIV-caused gen-
ome disturbance has also been discussed as a basis for
rod formation [46].
In SLONM with MGUS, not merely the aggregation of
paraproteins but rather their effects on autogenous anti-
gens, especially sarcomeric proteins, are thought to
cause the formation of rods [47, 48]. In fact, one case of
SLONM with MGUS was described with sarcolemmal
deposits of the paraprotein [10], and another suggested
immunoreactivity of the sarcolemma to IgG with the
paraprotein light chain [11], lending support to this the-
ory. However, a similar immunohistochemical pattern
was reported in another publication of a patient without
MGUS [28], suggesting a similar pathogenic pathway in
SLONM without MGUS. SLONM patients with accom-
panying autoimmune diseases such as systemic lupus er-
ythematosus (SLE) [49] or Sjögren’s syndrome [50] often
improved during immunosuppressive medication,
whereas the majority of SLONM cases showed a disap-
pointing response rate. This observation might hint at a
different nonimmunogenic cause. Another hypothesis
suggested that rod formation is part of a regenerative
process without the traditional features of muscle repair
[29]; however, our findings fail to support this assertion.
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The chronology of the appearance of rods in relation to
disease course varied: Nine cases did not show any rods at
symptom onset on light microscopy, but only in a subse-
quent biopsy (P 4) [8, 25, 26, 29, 49, 51–53]. Six cases re-
vealed rods only after severe clinical deterioration (P4) [8,
25, 29, 51, 52]. Interestingly, this clinical correlation has
also been observed the other way around: clinical im-
provement after auto-PBSCT was accompanied by the
disappearance of rods [54, 55] as well as paraprotein re-
duction in SLONM patients with MGUS [56]. Therefore,
multiple biopsies during the disease course may be neces-
sary to confirm the diagnosis of SLONM.
Overall, the pathomechanisms of SLONM remain
unsolved.
Conclusions
To conclude, SLONM can be difficult to diagnose in routine
clinical practice, not only because of its rarity, but also due
to several clinical mimics. However, if an adult patient pre-
sents with progressive limb, bulbar and/or respiratory weak-
ness, we recommend respiratory function testing as well as
a muscle biopsy that includes a Gomori’s trichrome stain in
order to identify nemaline rods. If rods are not visible by
light microscopy, additional electron microscopic studies are
indicated. In addition, all SLONM patients should be
screened for a concomitant MGUS or HIV infection, since
both have distinct therapeutic and prognostic implications.
Additional file
Additional file 1: Table S1. Genetic variants identified in patients with
SLONM using NGS and a panel of 283 genes. (DOC 72 kb)
Acknowledgements
We thank the patients and their families for participating in our study. We
are grateful to the technical and administrative personnel of the Department
of Neurology and the Institute of Neuropathology at the University Hospital
Aachen for their support.
Funding
This study was funded by a research grant to K.G.C. provided by the
Deutsche Gesellschaft für Muskelkranke (DGM) e.V. PVD holds a senior clinical
investigatorship of FWO-Vlaanderen.
Availability of data and materials
The datasets used during the current study are available from the
corresponding author on request.
Authors’ contributions
LJS: Conception and study design, study screening, data extraction and
compilation, statistical analysis, interpretation of results, drafting the manuscript.
TS, ANP, WS, ER, PVD, AF, SP, CH, AB, AM, JP, TT, DT, JR, PDJ, JJM, PVDB:
participation in patient recruitment and data assessment, review and revision of
the manuscript. JBS: Overall supervision of the clinical part of the study from
conception to completion, review and revision of the manuscript. JW: Overall
supervision of the neuropathological part of the study from conception to
completion, review and revision of the manuscript. KGC: Conception and study
design, interpretation of results, supervising the study, supervising the writing of
the manuscript, review and revision of the manuscript. All authors approved the
final manuscript.
Competing interests
DRT received consultancies from Covance Laboratories (UK) and GE-
Healthcare (UK), received a speaker honorarium from GE-Healthcare (UK) and
collaborated with Novartis Pharma Basel (Switzerland).
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was approved by the ethical committee of the University Hospital
RWTH Aachen (Germany). Written informed consent was obtained from the
participating patients.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Neurology, University Hospital RWTH Aachen, Aachen,
Germany. 2Institute of Neuropathology, University Hospital RWTH Aachen,
Aachen, Germany. 3Department of Neurology, Medizinisches Zentrum
StädteRegion Aachen, Würselen, Germany. 4Reference Centre for
Neuromuscular Diseases, Department of Neurology, University Hospital
Angers, Angers, France. 5Department of Neuropathology, Charité -
Universitätsmedizin Berlin, Berlin, Germany. 6Institute of Neuropathology,
University Hospital Zürich, Zürich, Switzerland. 7Department of Neurology,
University Hospitals Leuven, Leuven, Belgium. 8Department of Neurosciences,
Experimental Neurology, University of Leuven (KU Leuven), Leuven, Belgium.
9VIB, Center for Brain and Disease Research, Leuven, Belgium. 10Department
of Neurology, Klinikum Kassel, Kassel, Germany. 11Department of Neurology,
Hannover Medical School, Hannover, Germany. 12Department of
Neuropathology, Hannover Medical School, Hannover, Germany. 13Institute
of Neuropathology, University Hospital Tübingen, Tübingen, Germany.
14Department of Neurology, University Hospital Charité Berlin, Berlin,
Germany. 15Department of Neurology, University Hospital Zurich and
University of Zurich, Zurich, Switzerland. 16Department of Pathology,
University Hospitals Leuven, Leuven, Belgium. 17Department of
Neurosciences, Experimental Neurology, Laboratory for Neuropathology,
University of Leuven (KU Leuven), Leuven, Belgium. 18Department of
Neurology, University Hospital Bonn, Bonn, Germany. 19Department of
Neurology, University Hospital Antwerpen, Antwerpen, Belgium. 20Institute of
Molecular Genetics (VIB), University of Antwerpen, Antwerpen, Belgium.
21Born-Bunge Institute, University of Antwerpen, Antwerpen, Belgium.
22Department of Neurology, University Hospital Saint-Luc, Brussels, Belgium.
23JARA-BRAIN Institute Molecular Neuroscience and Neuroimaging,
Forschungszentrum Jülich GmbH and RWTH Aachen University, Aachen,
Germany. 24Laboratory for Muscle Diseases and Neuropathies, Department of
Neurosciences, Experimental Neurology, KU Leuven - University of Leuven,
Leuven, Belgium. 25Campus Gasthuisberg, Department of Neurology,
University Hospitals Leuven and KU Leuven (University of Leuven), Herestraat
49, B-3000 Leuven, Belgium.
Received: 29 December 2016 Accepted: 24 April 2017
References
1. Engel AG. Late-onset rod myopathy (a new syndrome?): light and electron
microscopic observations in two cases. Mayo Clin Proc. 1966;41(11):713–41.
2. Engel WK, Resnick JS. Late-onset rod myopathy: a newly recognized,
acquired, and progressive disease. Neurology. 1966;16:308–9.
3. Palmucci L, Doriguzzi C, Mongini T, Chiado-Piat L. Adult onset nemaline
myopathy: a distinct nosologic entity? Clin Neuropathol. 1993;12(3):153–5.
4. Engel WK, Oberc MA. Abundant nuclear rods in adult-onset rod disease. J
Neuropathol Exp Neurol. 1975;34(2):119–32.
5. Lomen-Hoerth C, Simmons ML, Dearmond SJ, Layzer RB. Adult-onset
nemaline myopathy: another cause of dropped head. Muscle Nerve. 1999;
22(8):1146–50.
6. Kelly E, Farrell MA, McElvaney NG. Adult-onset nemaline myopathy
presenting as respiratory failure. Respir Care. 2008;53(11):1490–4.
Schnitzler et al. Orphanet Journal of Rare Diseases  (2017) 12:86 Page 10 of 12
7. Whitaker J, Love S, Williams AP, Plummeridge M. Idiopathic adult-onset
nemaline myopathy presenting with isolated respiratory failure. Muscle
Nerve. 2009;39(3):406–8.
8. Gyure KA, Prayson RA, Estes ML. Adult-onset nemaline myopathy: a case report
and review of the literature. Arch Pathol Lab Med. 1997;121(11):1210–3.
9. Wengert O, Meisel A, Kress W, Dekomien G, Angstwurm K, Heppner FL,
Goebel HH, Stenzel W. Progressive external ophthalmoplegia as initial
manifestation of sporadic late-onset nemaline myopathy. J Neurol. 2011;
258(5):915–7.
10. Eymard B, Brouet JC, Collin H, Chevallay M, Bussel A, Fardeau M. Late-onset
rod myopathy associated with monoclonal gammopathy. Neuromuscul Dis.
1993;3(5–6):557–60.
11. Deconinck N, Laterre EC, Van den Bergh PY. Adult-onset nemaline
myopathy and monoclonal gammopathy: a case report. Acta Neurol Belg.
2000;100(1):34–40.
12. Chahin N, Selcen D, Engel AG. Sporadic late onset nemaline myopathy.
Neurology. 2005;65(8):1158–64.
13. Keller CE, Hays AP, Rowland LP, Moghadaszadeh B, Beggs AH, Bhagat G.
Adult-onset nemaline myopathy and monoclonal gammopathy. Arch
Neurol. 2006;63(1):132–4.
14. Dalakas MC, Pezeshkpour GH, Flaherty M. Progressive nemaline (rod)
myopathy associated with HIV infection. N Engl J Med. 1987;317(25):1602–3.
15. Gonzales MF, Olney RK, So YT, Greco CM, McQuinn BA, Miller RG,
DeArmond SJ. Subacute structural myopathy associated with human
immunodeficiency virus infection. Arch Neurol. 1988;45(5):585–7.
16. Simpson DM, Bender AN. Human immunodeficiency virus-associated
myopathy: analysis of 11 patients. Ann Neurol. 1988;24(1):79–84.
17. Dwyer BA, Mayer RF, Lee SC. Progressive nemaline (rod) myopathy as a
presentation of human immunodeficiency virus infection. Arch Neurol.
1992;49(5):440.
18. Cabello A, Martinez-Martin P, Gutierrez-Rivas E, Madero S. Myopathy with
nemaline structures associated with HIV infection. J Neurol. 1990;237(1):64–5.
19. Dubowitz V, Sewry CA, Oldfors A, Lane RJ. Muscle biopsy : a practical
approach. 4rthth ed. Oxford: Saunders Elsevier; 2013. p. 2013.
20. Price HM, Gordon GB, Pearson CM, Munsat TL, Blumberg JM. New evidence
for excessive accumulation of Z-band material in nemaline myopathy. Proc
Natl Acad Sci U S A. 1965;54(5):1398–406.
21. Paulus W, Peiffer J, Becker I, Roggendorf W, Schumm F. Adult-onset rod
disease with abundant intranuclear rods. J Neurol. 1988;235(6):343–7.
22. Goebel HH, Warlo I. Nemaline myopathy with intranuclear rods–intranuclear
rod myopathy. Neuromuscular Disord. 1997;7(1):13–9.
23. Malfatti E, Romero NB. Nemaline myopathies: State of the art. Rev Neurol.
2016;172(10):614–9.
24. Klarl BA, Bornemann A, Demuth K, Zahringer M, Lindner A. Sporadic adult
form of nemaline myopathy–a difficult differential diagnosis. Fortschr Neurol
Psychiatr. 2009;77(3):166–8.
25. Milone M, Katz A, Amato AA, Soderland CA, Segarceanu M, Young NP,
Jones HR. Sporadic late onset nemaline myopathy responsive to IVIg and
immunotherapy. Muscle Nerve. 2010;41(2):272–6.
26. Irodenko VS, Lee HS, de Armond SJ, Layzer RB. Adult nemaline myopathy
with trabecular muscle fibers. Muscle Nerve. 2009;39(6):871–5.
27. Montagnese F, Portaro S, Musumeci O, Migliorato A, Moggio M, Fagiolari G,
Rodolico C. Sporadic late-onset nemaline myopathy in a woman with
multiple myeloma successfully treated with lenalidomide/dexamethasone.
Muscle Nerve. 2015;51(6):934–5.
28. Reyes MG, Tal A, Abrahamson D, Schwartz M. Nemaline myopathy in an
adult with primary hypothyroidism. Can J Neurol Sci. 1986;13(2):117–9.
29. Letournel F, Le Clec’h C, Croue A, Marcorelles P, Lavigne C, Penisson-Besnier
I. Nemaline bodies as unique pathological feature in the course of treated
dermatomyositis. Clin Neuropathol. 2010;29(6):357–60.
30. Brownell AK, Gilbert JJ, Shaw DT, Garcia B, Wenkebach GF, Lam AK. Adult
onset nemaline myopathy. Neurology. 1978;28(12):1306–9.
31. Kemta Lekpa F, Chevalier X, Dubourg O, Dimitri D. Isolated camptocormia
revealing sporadic late onset nemaline myopathy. Presse medicale (Paris,
France : 1983). 2013;42(7–8):1142–4.
32. Centers for Disease C, Prevention. Revised surveillance case definition for HIV
infection–United States, 2014. MMWR Recomme Rep. 2014;63(Rr-03):1–10.
33. Huang J, Han C, Estacion M, Vasylyev D, Hoeijmakers JG, Gerrits MM,
Tyrrell L, Lauria G, Faber CG, Dib-Hajj SD, et al. Gain-of-function
mutations in sodium channel Na(v)1.9 in painful neuropathy. Brain.
2014;137(Pt 6):1627–42.
34. Lassuthova P, Mazanec R, Vondracek P, Siskova D, Haberlova J, Sabova J,
Seeman P. High frequency of SH3TC2 mutations in Czech HMSN I patients.
Clin Genet. 2011;80(4):334–45.
35. Lupski JR, Reid JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC, Nazareth L,
Bainbridge M, Dinh H, Jing C, Wheeler DA, et al. Whole-genome
sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J
Med. 2010;362(13):1181–91.
36. Paganoni S, Amato A. Electrodiagnostic evaluation of myopathies. Phys Med
Rehabil Clin N Am. 2013;24(1):193–207.
37. Preston DC, Shapiro BE. Clinical Electrophysiologic Correlations. In:
Electromyography and Neuromuscular Disorders. 3 edn. Boston: Mcgill J
Med. 2006;9(2):173. 2013:p. 554.
38. Gerard JM, Telerman-Toppet N, Borenstein S, Flament-Durand J. Sporadic Z
disk myopathy with accumulation of rods and cytoplasmic bodies. Rev
Neurol. 1991;147(2):144–7.
39. Sieb JP, VonOertzen J, Tolksdorf K, Dorfler P, Kappes-Horn K, Jerusalem F.
Sporadic adult-onset distal myopathy with rimmed vacuoles, 15–18 nm
tubulofilaments and extensive rod formation. J Neurol Sci. 1997;146(1):81–4.
40. Cakir M, Samanci N, Balci N, Balci MK. Musculoskeletal manifestations in
patients with thyroid disease. Clin Endocrinol (Oxf). 2003;59(2):162–7.
41. Shy GM, Engel WK, Somers JE, Wanko T. Nemaline myopathy. A new
congenital myopathy. Brain. 1963;86:793–810.
42. Miyatake S, Mitsuhashi S, Hayashi YK, Purevjav E, Nishikawa A, Koshimizu E,
Suzuki M, Yatabe K, Tanaka Y, Ogata K, et al. Biallelic mutations in MYPN,
encoding myopalladin, are associated with childhood-onset, slowly
progressive nemaline myopathy. Am J Hum Genet. 2017;100(1):169–78.
43. Goebel HH, Piirsoo A, Warlo I, Schofer O, Kehr S, Gaude M. Infantile
intranuclear rod myopathy. J Child Neurol. 1997;12(1):22–30.
44. Schroder JM, Durling H, Laing N. Actin myopathy with nemaline bodies,
intranuclear rods, and a heterozygous mutation in ACTA1 (Asp154Asn). Acta
Neuropathol. 2004;108(3):250–6.
45. de Sanctis JT, Cumbo-Nacheli G, Dobbie D, Baumgartner D. HIV-associated
nemaline rod myopathy: role of intravenous immunoglobulin therapy in
two persons with HIV/AIDS. AIDS Read. 2008;18(2):90–4.
46. Feinberg DM, Spiro AJ, Weidenheim KM. Distinct light microscopic changes
in human immunodeficiency virus-associated nemaline myopathy.
Neurology. 1998;50(2):529–31.
47. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108(8):2520–30.
48. Novy J, Rosselet A, Spertini O, Lobrinus JA, Pabst T, Kuntzer T.
Chemotherapy is successful in sporadic late onset nemaline myopathy
(SLONM) with monoclonal gammopathy. Muscle Nerve. 2010;41(2):286–7.
49. Dimitri D, Dubourg O. Sporadic late-onset nemaline myopathy in a patient
with systemic lupus erythematosus. J Neurol. 2013;260(12):3171–3.
50. Suzuki M, Shimizu Y, Takeuchi M, Kobayashi M, Iwata M, Uchiyama S.
Sporadic late-onset nemaline myopathy in a patient with primary Sjogren’s
syndrome. J Neurol. 2012;259(2):358–60.
51. Doppler K, Knop S, Einsele H, Sommer C, Wessig C. Sporadic late onset
nemaline myopathy and immunoglobulin deposition disease. Muscle Nerve.
2013;48(6):983–8.
52. Hanisch F, Schneider I, Muller T, Romeike BF, Stoltenburg G, Holzhausen HJ,
Zierz S. Treatability of sporadic late onset nemaline myopathy. Nervenarzt.
2013;84(8):955–61.
53. Kamieniecka Z. Late onset myopathy with rod-like particles. Acta Neurol
Scand. 1973;49(4):547–51.
54. Benveniste O, Laforet P, Dubourg O, Solly S, Musset L, Choquet S, Azar N,
Fardeau M, Herson S, Leblond V, et al. Stem cell transplantation in a patient
with late-onset nemaline myopathy and gammopathy. Neurology. 2008;
71(7):531–2.
55. Voermans NC, Minnema M, Lammens M, Schelhaas HJ, Kooi AV, Lokhorst
HM, van Engelen BG. Sporadic late-onset nemaline myopathy effectively
treated by melphalan and stem cell transplant. Neurology. 2008;71(7):532–4.
56. Voermans NC, Benveniste O, Minnema MC, Lokhorst H, Lammens M,
Meersseman W, Delforge M, Kuntzer T, Novy J, Pabst T, et al. Sporadic late-
onset nemaline myopathy with MGUS: long-term follow-up after melphalan
and SCT. Neurology. 2014;83(23):2133–9.
57. Katirji B, Hachwi R, Al-Shekhlee A, Cohen ML, Bohlman HH. Isolated dropped
head due to adult-onset nemaline myopathy treated by posterior fusion.
Neurology. 2005;65(9):1504–5.
58. Maeda MH, Ohta H, Izutsu K, Shimizu J, Uesaka Y. Sporadic late-onset
nemaline myopathy as a rare cause of slowly progressive muscle weakness
with young adult onset. Muscle Nerve. 2015;51(5):772–4.
Schnitzler et al. Orphanet Journal of Rare Diseases  (2017) 12:86 Page 11 of 12
59. Seitz RJ, Toyka KV, Wechsler W. Adult-onset mixed myopathy with nemaline
rods, minicores, and central cores: a muscle disorder mimicking
polymyositis. J Neurol. 1984;231(3):103–8.
60. Sun AP, Ohtsuki Y, Yano T, Matsumoto M, Takeuchi T, Furihata M, Arahori M,
Sonobe H. Typical nemaline bodies presenting in a patient with
polymyositis. Med Electron Microsc. 2002;35(3):167–72.
61. Danon MJ, Giometti CS, Manaligod JR, Perurena OH, Skosey JL. Adult-onset
nemaline rods in a patient treated for suspected dermatomyositis. Study
with two-dimensional electrophoresis. Arch Neurol. 1981;38(12):761–6.
62. Parks NE, Hanada EY. Maximizing functional independence in sporadic late
onset nemaline myopathy. PM & R. 2012;4(12):1020–3.
63. Falga-Tirado C, Perez-Peman P, Ordi-Ros J, Bofill JM, Balcells E. Adult onset
of nemaline myopathy presenting as respiratory insufficiency. Respiration.
1995;62(6):353–4.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to ﬁnd the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Schnitzler et al. Orphanet Journal of Rare Diseases  (2017) 12:86 Page 12 of 12
